|
Accession Number
|
ADA564160
|
|
Title
|
Role of Receptor Sialylation in the Ovarian Tumor Cell Phenotype.
|
|
Publication Date
|
Jun 2012
|
|
Media Count
|
8p
|
|
Personal Author
|
S. L. Bellis
|
|
Abstract
|
The overarching goal of our research is to define the role of a cancer-associated glycosyltransferase, ST6Gal-I, in regulating the ovarian tumor cell phenotype. In the first year of this pilot project, significant progress has been made toward establishing ST6Gal-I s function in protecting tumor cells from apoptosis. These results establish a new paradigm in apoptotic signaling, particularly given that there is a marked dearth of evidence concerning glycosylation-dependent mechanisms in tumor cell survival. We also show that tumor cells can be sensitized to cisplatin-induced cell death through forced downregulation of ST6Gal-I. Platin drugs represent a first-line treatment for ovarian cancer, therefore therapeutic targeting of ST6Gal-I may hold promise for treating patients that have become chemoresistant. Finally, preliminary results indicate that ST6Gal-I protein is upregulated in human ovarian tumors, implicating ST6Gal-I as a potential new biomarker. In the upcoming year, our studies will focus on elucidating the mechanistic basis by which ST6Gal-I modulates the activity of integrins and death receptors to control tumor cell invasion and apoptosis-resistance.
|
|
Keywords
|
Apoptosis
Cells(Biology)
Chemoresistance
Death
Death receptors
Drugs
Galectin
Glycosylation
Invasion
Metastasis
Metastasis disease
Neoplasms
Ovarian cancer
Ovarian cancer cells
Ovaries
Patients
Receptor sites(Physiology)
Sialic acids
Therapy
|
|
|
Source Agency
|
Non Paid ADAS
|
|
NTIS Subject Category
|
57E - Clinical Medicine
57B - Biochemistry
|
|
Corporate Author
|
Alabama Univ. in Birmingham.
|
|
Document Type
|
Technical report
|
|
Title Note
|
Annual rept. 15 May 2011-14 May 2012.
|
|
NTIS Issue Number
|
1302
|
|
Contract Number
|
W81XWH-11-1-0404
|
